Stay updated on Nivolumab and Ipilimumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Ipilimumab in Melanoma Clinical Trial page.

Latest updates to the Nivolumab and Ipilimumab in Melanoma Clinical Trial page
- Check6 days agoChange DetectedThe page now shows Revision: v3.5.4, replacing v3.5.3, indicating a new site build. The change does not alter the study details or user-facing information.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe page’s site revision/version indicator was updated from v3.5.2 to v3.5.3, reflecting a maintenance or platform update rather than a change to the clinical trial information.SummaryDifference0.0%

- Check35 days agoChange DetectedAdded Melanoma as a topic and related topics (MedlinePlus Genetics); updated revision to v3.5.2 and removed v3.5.0.SummaryDifference0.1%

- Check42 days agoChange DetectedThe Italy site entry was updated from Padua, Italy 35128 to Padova, Italy 35128.SummaryDifference0.0%

- Check49 days agoChange DetectedThe Melanoma topic, related topics, and MedlinePlus Genetics were removed from the page.SummaryDifference0.1%

- Check57 days agoChange DetectedNaples, Italy, 80131 was added as a location and Napoli, Italy, 80131 was removed; Melanoma and related topics, including MedlinePlus Genetics, were added to the related topics section.SummaryDifference0.1%

Stay in the know with updates to Nivolumab and Ipilimumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Ipilimumab in Melanoma Clinical Trial page.